CAJ | 학술논문

目的：结合体内外实验研究南蛇藤提取物对人肝癌细胞HepG2上皮间质转化的作用及分子机制。方法：取对数生长期HepG2细胞，除对照组外，分别给予南蛇藤提取物10、20、40、80、160滋g·mL-1培养，采用Western Blotting法检测上皮间质转化（EMT）相关蛋白的表达水平；斑马鱼胚胎，于受精后48 h开始给药，正常组给予E3缓冲液，DMSO组为含1% DMSO的E3缓冲液，南蛇藤组各药物浓度分别为10、20、40、80、160滋g·mL-1；给药24 h后，以Western Blotting法检测mTOR信号通路相关蛋白的表达水平。结果：与对照组相比，南蛇藤提取物各浓度组明显增加E-cadherin的表达量，降低vimentin和mTOR信号通路相关蛋白的表达水平。结论：南蛇藤提取物能在一定程度上逆转人肝癌细胞EMT ，其分子机制可能与mTOR信号通路相关，mTOR可作为临床治疗肝癌的新靶点。
목적：결합체내외실험연구남사등제취물대인간암세포HepG2상피간질전화적작용급분자궤제。방법：취대수생장기HepG2세포，제대조조외，분별급여남사등제취물10、20、40、80、160자g·mL-1배양，채용Western Blotting법검측상피간질전화（EMT）상관단백적표체수평；반마어배태，우수정후48 h개시급약，정상조급여E3완충액，DMSO조위함1% DMSO적E3완충액，남사등조각약물농도분별위10、20、40、80、160자g·mL-1；급약24 h후，이Western Blotting법검측mTOR신호통로상관단백적표체수평。결과：여대조조상비，남사등제취물각농도조명현증가E-cadherin적표체량，강저vimentin화mTOR신호통로상관단백적표체수평。결론：남사등제취물능재일정정도상역전인간암세포EMT ，기분자궤제가능여mTOR신호통로상관，mTOR가작위림상치료간암적신파점。
This study was aimed to investigate the effect of Nan-She-Teng (Celastrus orbiculatus) extract on epithe-lial-mesenchymal transition(EMT) in HepG2 cells. Except the control group, human hepatocellular carcinoma HepG2 cells in other groups were treated with Celastrus Orbiculatus extract in different concentrations (10, 20, 40, 80, and 160 μg·mL-1). The protein expression levels related to EMT were detected by western blotting. At 48 h after fertiliza-tion, the zebrafish embryos were randomly assigned to 7 groups as follows: untreated control group (E3 buffer), DMSO group (E3 buffer with 1% DMSO), and different dosages treatment of C.orbiculatus extract (10, 20, 40, 80, and 160μg·mL-1) for 24 h. The protein expressions of mTOR signaling pathways were detected by western blotting. The re-sults showed that compared with the control group, C.orbiculatus extract significantly increased E-cadherin protein expression. Simultaneously, C.orbiculatus extract inhibited vimentin and mTOR signaling pathways at protein levels. It was concluded that to a certain extent, C.orbiculatus extract prevented EMT in HepG2 cells by modulating the mTOR signaling pathway. Therefore, it suggested that mTOR can be chosen as a new therapeutic target for clinical treatment of hepatic carcinoma.